vrdct.Open terminal

Biotech liquidity.
One continuous VLP.

VLP is the ongoing liquidity vehicle behind VRDCT. Hold one ERC20 token across event-market strategies. Earn the portfolio’s provider fees and carry its inventory results, with continuous proportional entry and exit.

Understand VLPExplore the markets

Research / sandbox. Native VLP is not deployed. No live deposits.

A drug milestone becomes an onchain outcome marketPrimary evidence defines an event rule. One USDC creates a YES and NO pair. Traders exchange these claims, while VLP can supply AMM inventory.DRUG EVIDENCETRIAL · FILING · LABELONE DEFINED EVENTFDA approvalExact drug. Exact indication.RULE + CUTOFF + ORACLEYES70¢NO30¢ONCHAIN MARKETERC20 CLAIMS / USDC BACKING
Evidence becomes a tradable event.Illustrative 70/30 prices. No live quote.

One position.
An ongoing market.

VLP is designed to keep running as events come and go. New holders join the same portfolio proportionally. Departing holders take their portion—not somebody else’s liquidity.

Your maximum spend130USDC

You accept a funded maker quote.

Actual proportional basket1% of pre-entry holdings
100USDCCash balance
20receiptsEvent sleeve A
30receiptsEvent sleeve B
New ownership100VLP

The maker supplies this basket. Shares mint only after the assets arrive.

Your payment goes to the quoting maker. The vault receives its exact proportional assets, so a cheap quote cannot dilute existing holders.

Illustrative basket and external quotes—not a live price or NAV. Cash routes require funded counterparties. Basket redemption is not guaranteed immediate cash. No live VLP is deployed.

Trade the event.

Express a view on an approval or readout without taking every risk on a company’s balance sheet.

An event claim is not a complete stock hedge.

Supply the market.

Hold a share of liquidity strategies that supply AMMs and receive their allocated execution fees.

Provider income comes with inventory exposure.

Use familiar rails.

Standard ERC20 YES/NO claims, explicit USDC backing and rules fixed before a market opens.

Claims give no company equity or drug IP.

A new way to connect
biotech conviction
with onchain capital.

Biotech creates discrete moments of uncertainty. VRDCT turns a precisely defined event into a pair of tradable claims. VLP adds an inventory-backed liquidity layer around them.

YES trader

700 USDC

Receives 1,000 YES

700300
Reserved backing1,000 USDC
1,000 YES1,000 NO

One USDC backs each complete pair.

NO trader

300 USDC

Receives 1,000 NO

More open interest. No VLP capital required.

Opposing buyers can supply the complete backing together. VLP adds liquidity around that demand; it does not need to fund every dollar of open interest.

Buying an existing claim transfers ownership; it does not create additional open interest. Fees excluded from these funding examples.

Own the liquidity.
Earn the activity.

VLP holders own a pro-rata interest in the portfolio: USDC, event-sleeve receipts and the inventory economics and allocated fees behind them.

Execution fees+Inventory result=Cohort result

Fee revenue is earned when the pool trades. Inventory gains or losses arrive with the event. Fees can be smaller than losses; no APY or positive return is established.

1,000face traded at 70/30
Smaller consideration300 × 0.50%1.50 USDC fee
1.05Provider / 70%
0.45Protocol / 30%
Illustrative native fee fixture, not approved production terms. VLP receives the provider share on its own AMM fills, not external makers’ trades.

Many markets.
An ongoing portfolio.
Distinct risk budgets.

There is no preset launch count or universal dollar cap. Continuous VLP ownership sits above event-specific strategies. Each sleeve keeps its declared allocation and risk terms; the portfolio can retain cash and add new sleeves as opportunities arrive. This diagram illustrates one sleeve, not the whole vault.

Illustrative cohort100,000 USDC
Pool inventory25,000
USDC reserve75,000

Before accepting a fill, the pool checks its remaining cash and worst-state inventory value.

10,000 modeled loss budget
Reference parameters, not committed capital. The floor constrains inventory exposure; it does not insure principal or cover every contract, collateral or oracle failure.

The vehicle continues.
The events turn over.

Your VLP token need not wait for every event to finish. Enter or exit proportionally; funded maker quotes can convert between USDC and the actual basket. Underlying event receipts keep their own settlement terms.

Enter VLP

Contribute the proportional basket, directly or through a funded USDC quote.

ERC20 shares

Supply liquidity

Event sleeves hold AMM inventory and collect their provider share of fees.

Ongoing portfolio

Exit your share

Receive your proportional assets, or accept a funded quote for USDC.

No stale-NAV cash promise

Recycle capital

Settled sleeves return cash. The vehicle can allocate to new reviewed events.

New event exposure

Oracle disputes can delay underlying settlement. USDC conversion depends on funded quotes; in-kind exits retain the unresolved exposure. Read the full risk terms

See what inventory
actually means.

Change the outcomes in a separate three-event example. Follow the claims through YES, NO and INVALID. This illustrates event-sleeve accounting, not a continuous-vault forecast or a live portfolio.

Open the inventory lab
Starting capital$10,000
Premium received$2,050
Backing locked$3,500
Cash on hand$8,550

Change the outcomes.

Fictional events
A
Regulatory decisionSold 2,000 YES @ 80¢
B
Trial endpointSold 1,000 NO @ 40¢
C
Label expansionSold 500 NO @ 10¢
Retained claims pay$1,000
Terminal cash$9,550
Inventory P&L−$450

Cash on hand $8,550 + retained-claim payout $1,000 = final cash $9,550. Premium is already inside cash on hand.

Every binary state.

No probabilities assumed
A / B / CCohort P&L
−$1,4500+$2,050

Y = YES · N = NO. Click a row to replay that combination. No diversification credit is assumed.

A $10,000 example, not a fundraising target. Direct-claim underwriting, not the current FPMM. All cash values are illustrative USDC; fees, expenses and execution are excluded. Cash on hand is not an instant withdrawal allowance. Eight valid binary combinations are shown. INVALID splits each claim’s backing 50/50; disputes can delay settlement. This is accounting, not a production risk engine or a forecast.

From drug milestones
to a market you can use.

Research the event. Trade the claim. Supply liquidity behind it. Biotech expertise and DeFi execution meet in one defined market.

Explore VRDCTStart with the evidence